Given the prominent findings from the manifest disease phase, smaller studies have focused on non-PD-manifest GBA1 mutation carriers who did not meet diagnostic criteria for manifest PD or DLB at time of assessment (GBA1NMC)11. Here, GBA1 is linked to Parkinson disease.